Related Experiment Video
Updated: Jul 28, 2026
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
SLFN11 Drives GM-CSF-mediated M1 Macrophage Polarization and Enhances Immunotherapy Response in Renal Cell Carcinoma
Yohei Okuda1, Junko Murai2,3, Tsuyoshi Takashima4,5
1Department of Urology, The University of Osaka Graduate School of Medicine, Osaka, Japan.
Background/Aim:
Advanced renal cell carcinoma (RCC) is commonly treated with immune checkpoint inhibitor (ICI)-based therapies. However, patient responses vary, and predictive biomarkers remain limited. Here, we demonstrate that Schlafen 11 (SLFN11), which has emerged as an important gene in immunity and drug response, acts as a key enhancer of antitumor immunity in advanced RCC.
Materials And Methods:
We analyzed transcriptome data from in-house and public RCC patient cohorts to evaluate associations between SLFN11 expression, clinical outcomes, and immune contexture. Transcriptome profiling of RCC cell lines was performed to identify SLFN11-regulated cytokines. Functional assays included co-culture of wild-type or SLFN11-knockout RCC cells with M0 macrophages, immature macrophages, followed by cytokine quantification and phenotypic analyses. Multiplex immunofluorescence staining was applied to formalin-fixed paraffin-embedded samples from ICI-treated patients to validate immune cell infiltration in the tumor microenvironment.
Results:
Clinically, patients with SLFN11-high RCC treated with ICI-based regimen showed significantly prolonged progression-free survival in both our cohort and public datasets. SLFN11-high RCC tumors exhibited increased infiltration of anti-tumoral M1 macrophages and up-regulation of immune-related pathways compared to SLFN11-low tumors. Mechanistically, transcriptome as well as proteome analysis revealed that, in RCC cells, SLFN11 significantly up-regulated the expression of colony stimulating factor 2 (CSF2) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), which promotes polarization from M0 macrophages to M1 macrophages. Consequently, SLFN11-positive RCC cells co-cultured with M0 macrophages secreted significantly higher levels of GM-CSF than SLFN11-negative cells and promoted M1 macrophage differentiation. Consistently, multiplex immunofluorescence staining of RCC patient sample analysis confirmed that the number of M1 macrophages was significantly higher in the tumor microenvironment of SLFN11-high tumor than in SLFN11-low tumor.
Conclusion:
SLFN11 enhances antitumor immunity in RCC by increasing GM-CSF secretion and activating M1 macrophages, potentially improving ICI efficacy.
Insights
Schlafen 11 (SLFN11) enhances antitumor immunity in advanced renal cell carcinoma (RCC) by boosting granulocyte-macrophage colony-stimulating factor (GM-CSF) and promoting M1 macrophage activation, potentially improving immune checkpoint inhibitor (ICI) therapy efficacy.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Advanced renal cell carcinoma (RCC) treatment relies on immune checkpoint inhibitors (ICIs), but patient responses vary due to limited predictive biomarkers.
- Schlafen 11 (SLFN11) has emerged as a significant gene influencing immunity and drug response.
Purpose of the Study:
- To investigate the role of SLFN11 as a potential biomarker and enhancer of antitumor immunity in advanced RCC.
- To elucidate the mechanism by which SLFN11 influences the tumor immune microenvironment and response to ICI therapy.
Main Methods:
- Analysis of transcriptome data from RCC patient cohorts to correlate SLFN11 expression with clinical outcomes and immune contexture.
- Functional assays involving co-culture of RCC cells with macrophages to assess SLFN11-regulated cytokine production and macrophage polarization.
- Multiplex immunofluorescence staining of patient samples to validate immune cell infiltration in the tumor microenvironment.
Main Results:
- Patients with SLFN11-high RCC treated with ICIs demonstrated significantly prolonged progression-free survival.
- SLFN11-high tumors showed increased infiltration of M1 macrophages and enhanced immune-related pathways.
- SLFN11 up-regulates granulocyte-macrophage colony-stimulating factor (GM-CSF) expression in RCC cells, promoting M1 macrophage differentiation.
Conclusions:
- SLFN11 enhances antitumor immunity in RCC by increasing GM-CSF secretion and activating M1 macrophages.
- SLFN11 may serve as a predictive biomarker for ICI therapy and a therapeutic target to improve treatment efficacy in advanced RCC.
